Search

Introduction: Femoral-femoral Veno-Venous ExtraCorporeal Life Support (V-V ECLS) has been associated with higher infections rates, vascular site bleeding complications, and restricted patient mobility. Jugular or bicaval dual lumen V-V ECLS conceptually overcomes some of these adverse factors, but experience has shown that jugular vein cannulation still limits mobility and has increased bleeding complications. Technique and outcomes of subclavian vein single-cannulation with Crescent jugular dual-lumen V-V ECLS is described. Method: five patients with COVID-19 related acute respiratory distress syndrome (ARDS) underwent right subclavian vein V-V ECLS placement with the Crescent 32 French jugular dual-lumen V-V ECLS catheter. A standardized percutaneous technique was developed that allowed efficient insertion without need for any specialized imaging (i.e. transesophageal echocardiogram) and outcomes assessed. Results: Mean age of the five patients was 41.2 years, all obese with an average basal mass index of 45.2 kg/m2 and mean days to decannulation of 24.2 days. Outcomes discovered included; improved patient mobility allowing physical rehabilitation, no vascular access site related complications requiring surgery or endovascular intervention, and none had evidence of superior vena cava syndrome. One patient had subclavian/axillary vein thrombosis with resolution after 3 months of direct-acting oral anticoagulants, and one patient had blood cultures positive at day 37, nearing decannulation. Conclusion: Subclavian vein access for crescent jugular dual lumen V-V ECLS catheter appears to be safe and feasible with added benefits of decreased bleeding and increased mobility over jugular or femoral-femoral access site for long term V-V ECLS support in COVID-19 related ARDS patients. [ABSTRACT FROM AUTHOR]

Background Fibrillary glomerulonephritis (FGN) is a rare type of glomerulonephritis with poor prognosis, with no known effective therapies available for treatment. The objective of the study was to evaluate the efficacy and safety of rituximab in treatment of patients with FGN and to investigate the effect of rituximab on DNAJB9 levels. Methods This was a pilot prospective clinical trial in which patients with idiopathic FGN were treated with two courses of rituximab (1 g each) 2 weeks apart at the beginning and then again at 6 months. Primary outcome was defined as preservation of kidney function at 12 months with stable or increased creatinine clearance. Secondary outcome was defined as achieving complete remission (CR) defined as proteinuria <300 mg/24 h or partial remission (PR) with proteinuria <3 g/24 h and at least 50% reduction in the proteinuria. DNAJB9 levels were also measured in the serum at baseline, 6 and 12 months. Results The creatinine clearance did not change significantly during this time, from 47.7 mL/min/1.73 m2 at baseline to 43.7 mL/min/1.73 m2 during follow-up (P = 0.15). Proteinuria declined from 4.43 (1.6–5.53) g/24 h at baseline to 1.9 (0.46–5.26) g/24 h at 12 months but did not reach significance (P = 0.06). None of the patients reached CR, and 3 of the 11 achieved PR. There was no change in the DNAJB9 levels following treatment with rituximab. The most common adverse event was nasal congestion, fatigue and muscle cramps. Conclusions Treatment of patients with two courses of rituximab over a span of 6 months was associated with stabilization of renal function but did not result in a significant change in proteinuria and with no change in the DNAJB9 levels. [ABSTRACT FROM AUTHOR]

PURPOSE: Main purpose of this study is to correlate heart murmur and preventive cardiological examination to the existence of heart disease in childhood. MATERIAL AND METHODS: We examined 315 newborns, infants, children and adolescents that were referred to our Department either because of audible heart murmur or for preventive cardiological examination. Subjects were divided into three age groups. Group A (newborns n=37), Group B (infants n=91) and Group C (Children and Adolescents n=177). RESULTS: In Group A 62,1 % of those examined for heart murmur had heart disease and 19% no heart disease. 11% of newborns referred for preventive examination were diagnosed with heart disease and 7,9 % without heart disease. In Group B 30,7% of those examined for heart murmur had heart disease and 40,6% no heart disease. Also, 16,5% of those referred for preventive examination had heart disease and 12,2% no heart disease. In Group C 3,9% of those examined for heart murmur had heart disease and 19,8% no heart disease. Also, 13% of those referred for preventive examination had heart disease and 63,3% no heart disease. CONCLUSION: The audible heart murmur in newborns and infants is a powerful indication for cardiological examination. For fi rst time audible heart murmur in children and older ages, is usually the ‘'innocent'' heart murmur in childhood. The preventive cardiological examination should be performed in all children and adolescent, mainly before they participate in sport activities. [ABSTRACT FROM AUTHOR]